Pemivibart

N/A

Report date: 2025/06/10 15:04:54

Base Information

Drug NamePemivibart
Drug Alias NamePEMGARDAPemgardaVYD-222
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Coronavirus spike glycoproteinVirus attachment inhibitorsVirus internalization inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/03/05
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesInvivyd Inc
China Registration ClassN/A

Develop Information

Active CompaniesInvivyd Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank